logo
Adult social care vacancies down but domestic recruitment still ‘challenging'

Adult social care vacancies down but domestic recruitment still ‘challenging'

Yahoo18 hours ago
The number of jobs in adult social care in England filled by British nationals has fallen by 85,000 since the pandemic, according to a report which warns of challenges ahead for recruitment in the long-stretched sector.
Posts filled by people with a British nationality since 2020/2021 fell by 7%.
The Government has previously pledged to 'end the reliance on overseas recruitment' but Skills for Care's latest report has said there must be a focus on 'how we attract and keep more people domestically'.
In the most recent year alone, the twelve months to March, the number of posts filled by British nationals fell by 30,000, the organisation, which is the strategic workforce development and planning body for adult social care in England, said.
The organisation measures posts filled rather than the number of people, because a person might hold more than one post and roles might also be shared.
In rules which came into effect last week, new applications for care workers and senior care workers under the skilled worker visa were closed, as part of Government efforts in 'restoring control over the immigration system'.
In April the Government implemented new rules saying that care providers would have to prove they had attempted to recruit a worker from within England, before looking overseas.
The latest Skills for Care report said domestic recruitment 'remains challenging for the sector' and that the new immigration rules from July 'will make it more challenging for the sector to continue to grow in line with demand'.
The organisation re-stated its previous projection that an extra 470,000 people will need to be employed in the sector by 2040 to meet the needs of a growing older population.
The report said: 'A substantial increase in recruitment and retention of staff with a British nationality would likely be required to achieve this level of growth.'
Under the previous Conservative government, a ban on international care workers bringing dependants to the UK led to a sharp drop in health and care visas in the months after the measure came in.
The latest Skills for Care report said an estimated 50,000 people arrived in the UK in 2024/25 to start direct care-providing roles in the independent sector, down from 105,000 the previous year.
Of the 50,000 recruited internationally, an estimated 10,000 came on a health and care worker visa, while the rest came on other routes, potentially including student visas and family members of people arriving in the UK on other visa types.
Overall, the number of adult social care posts filled between 2023/24 and 2024/25 rose by 52,000 to 1.6 million.
The vacancy rate has also fallen to 7.0%, with 111,000 vacant posts on any given day in the year to March.
This is down from an 8.3% vacancy rate in the year to March 2024, when there were 126,000 vacant posts on any given day.
The vacancy rate hit a high of 152,000 vacant posts a day in the 12 months to March 2022.
Oonagh Smyth, Skills for Care's chief executive, said while the falling vacancy rate is 'encouraging', the sector 'can't afford to be complacent'.
She said: 'We need to protect ourselves from the wild swings in vacancy rates driven by the wider economic picture.
'It's important to recognise that, while the vacancy rate in social care has reduced, it's still three times that of the wider economy.'
She urged investment in 'stable recruitment and retention' and efforts to make roles 'more attractive to the domestic workforce over the long term' including through development opportunities, improving the quality of roles and supporting positive cultures within organisations.
She added: 'We know there's lots more to do, though. Everyone, from Government to care providers, from regulators to frontline staff, has a role to play in building the workforce we need to deliver the best possible care and support for the people in our communities who draw on local services.'
The Government has been contacted for comment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Donald Trump's Hands Under Scrutiny in New Photos
Donald Trump's Hands Under Scrutiny in New Photos

Newsweek

time4 hours ago

  • Newsweek

Donald Trump's Hands Under Scrutiny in New Photos

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. New photos of President Donald Trump's hands have led to renewed scrutiny about his health. Posting on social media, users have shared images of Trump during his visit to Europe, saying his hands are "swollen and bruised." Others suggested he was wearing makeup to conceal bruises. Why It Matters Earlier this month, the White House announced that Trump, who became the oldest person sworn in as president at the beginning of his second term, had been diagnosed with chronic venous insufficiency (CVI), something his doctor described as "benign and common." CVI is a condition in which the veins in the legs are unable to efficiently return blood to the heart. It is not life-threatening. The White House's announcement came after photos of Trump at various events showed swelling in his legs and bruises on his hands, which sparked public scrutiny about his health and fitness. Some have called for the 79-year-old to release his full medical records. President Donald Trump clasps his hands as he speaks with the media during a meeting with British Prime Minister Keir Starmer at the Trump Turnberry golf course in Scotland on July 28. President Donald Trump clasps his hands as he speaks with the media during a meeting with British Prime Minister Keir Starmer at the Trump Turnberry golf course in Scotland on July 28. AP Photo/Jacquelyn Martin What To Know X users weighed in on photos taken of Trump's hands during his recent trip to Scotland, where he met EU leaders. One user posted a video of the president's hands, saying Trump's signs of CVI had been "reportedly covered with makeup." Democratic activist Chris D. Jackson posted an image and added: "Wow. Look at those swollen and bruised hands in this photo from yesterday. Trump is not well." Another user replied, "So bad they're putting makeup on them." Age was a key theme of debate in last year's presidential election, with Trump often criticizing his opponent, then-President Joe Biden, as being too old to lead. Amid the increased scrutiny over Trump's fitness, White House press secretary Karoline Leavitt said, "The president remains in excellent health." At a news briefing, she said the president's medical team found "no evidence of deep vein thrombosis or arterial disease" and that he was not experiencing any discomfort related to CVI. Leavitt added that the bruise on his hand was consistent with irritation from "frequent handshaking and the use of aspirin." What People Are Saying Sean Barbabella, the president's physician, wrote in a memo: "The president underwent a comprehensive examination, including diagnostic vascular studies. Bilateral lower extremity venous Doppler ultrasounds were performed and revealed chronic venous insufficiency, a benign and common condition, particularly in individuals over the age of 70." Dr. Brian Funaki, a leading expert in vascular and interventional radiology at the University of Chicago Medicine, previously told Newsweek: "Generally speaking it is not life-threatening in and of itself, but it can predispose to developing blood clots in the veins in the legs—which, in the worst-case scenario, could break off and migrate to the lungs, causing pulmonary emboli, which can be fatal. This is why some people with this condition are treated with anticoagulation or other means, such as an inferior vena cava filter, which is a device designed to catch migrating blood clots." What Happens Next Though Trump's medical team has said he is in good health, scrutiny over his health is likely to continue.

Medimaps Group Collaborates with National Spine Health Foundation to Advance AI-Based Bone Fragility Assessment in Spine Surgery
Medimaps Group Collaborates with National Spine Health Foundation to Advance AI-Based Bone Fragility Assessment in Spine Surgery

Business Wire

time5 hours ago

  • Business Wire

Medimaps Group Collaborates with National Spine Health Foundation to Advance AI-Based Bone Fragility Assessment in Spine Surgery

GENEVA, Switzerland--(BUSINESS WIRE)--Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, today announced a new clinical research partnership with the National Spine Health Foundation (NSHF) - a nonprofit organization dedicated to patient education, research, and advocacy. Preoperative assessments of bone quality are critical for surgical planning and rehabilitation. Yet, bone fragility remains underdiagnosed in routine care. In this study, we will examine if TBS Reveal has the potential to fill this gap. Share The study, coordinated by NSHF and conducted at Mayo Clinic under the direction of Benjamin Elder, M.D., Ph.D., neurosurgeon and principal investigator, will evaluate the role of TBS Reveal for identifying spine surgery patients at elevated risk of intra- and post-operative bone fragility-related complications. The software uses standard preoperative X-rays and CT scans to derive Trabecular Bone Score (TBS) and a Bone Fragility Index, offering an AI-enhanced assessment of bone quality. Dr. Elder is a world recognized authority in spinal deformity, spinal oncology, and regenerative spine surgery. He directs Mayo Clinic's Stem Cell Therapeutics and Tissue Engineering Lab, with a focus on advancing bone health in spinal care. 'Preoperative assessments of bone quality are critical for surgical planning and rehabilitation,' said Univ. Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group. 'Yet, bone fragility remains underdiagnosed in routine care. In this study, we will examine if TBS Reveal has the potential to fill this gap using widely available imaging and advanced AI interpretation. While originally developed as an opportunistic screening tool, this study will explore its potential role as a purposeful, on-demand assessment method in high-risk surgical populations such as those undergoing spine procedures.' In the United States alone, over 1.2 million spine surgeries are performed each year. Published data indicate that up to 46% of spinal fusions and one-third of lumbar decompressions result in complications, many of which are associated with poor bone quality 1-2. This collaboration reflects Medimaps Group's ongoing commitment to advancing bone health assessment through partnerships with leading academic and clinical institutions. By combining real-world data, AI-powered tools, and expert clinical insight, the company aims to improve surgical outcomes and support broader adoption of bone fragility assessment in musculoskeletal care. References 1. Alhaug, O.K., Dolatowski, F.C., Solberg, T.K. and Lønne, G., 2023. Predictors for failure after surgery for lumbar spinal stenosis: a prospective observational study. The Spine Journal, 23 (2), pp.261-270. S., 2013. Failed back surgery syndrome–definition, epidemiology and demographics. British journal of pain, 7 (1), pp.56-59. About the National Spine Health Foundation The National Spine Health Foundation (NSHF), a 501-C(3) public charity, is the only patient-centered non-profit organization dedicated to helping patients over the spectrum of spine health challenges through patient education, advocacy and clinical research. Learn more at About Medimaps Group Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management.​ We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment. Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company's DNA.​ Medimaps Group, headquartered in Geneva, Switzerland, has offices in the United States and France. Its U.S. affiliate, Medimaps Group USA LLC, markets the company products and services in the United States. Learn more at

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk

Yahoo

time5 hours ago

  • Yahoo

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk

Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store